Does PRP Significantly Improve Diabetic Ulcer Healing?
Most forms of platelet-rich plasma (PRP) should NOT be routinely used for diabetic foot ulcers, with one critical exception: autologous leucocyte, platelet, and fibrin patch may be considered only after standard care has failed. 1
The Evidence-Based Recommendation
The 2024 IWGDF guidelines—the most authoritative and recent guidance on diabetic foot ulcer management—make a clear distinction that is crucial for clinical practice:
What NOT to Use (Strong/Conditional Recommendation Against)
The guidelines explicitly state: "With the exception of autologous leucocyte, platelet, and fibrin patch, we suggest not using autologous platelets therapy (including blood bank‐derived platelets) as an adjunct therapy to standard of care." 1
This recommendation is based on:
- 15 RCTs examining various platelet gel products 1
- All studies showed high risk of bias
- Only one study had outcome blinding, and it showed low certainty results 1
- The requirement for moderate volumes of autologous blood makes these preparations impractical
- Blood bank-derived platelets also failed to show convincing benefit 1
The ONE Exception: Leucocyte, Platelet, and Fibrin Patch
"Consider the use of autologous leucocyte, platelet, and fibrin patch for diabetes‐related foot ulcers as an adjunctive therapy to standard of care where best standard of care alone has been ineffective and where the resources and expertise exist for the regular venepuncture required (Conditional; Moderate)." 1
This specific recommendation is supported by:
- One high-quality, multicentre, outcome-blinded RCT at low risk of bias 1
- Demonstrated significant improvements in healing, time to healing, and wound area reduction at 20 and 26 weeks 1
- Weekly treatment protocol required 1
- Moderate quality evidence—the highest quality evidence for any platelet-based therapy in the entire guideline 1
Clinical Algorithm for Decision-Making
Step 1: Optimize Standard of Care FIRST
Before considering any platelet therapy:
- Sharp debridement performed
- Appropriate off-loading established
- Infection controlled
- Vascular status optimized
- Glycemic control addressed
- Basic wound dressings applied
- Minimum 2-4 weeks of optimal standard care attempted
Step 2: Assess for Leucocyte/Platelet/Fibrin Patch Candidacy
Only if standard care fails, consider this specific product if:
- Resources exist for weekly venepuncture
- Expertise available for preparation
- Patient can commit to weekly treatments
- Hard-to-heal ulcers (neuro-ischemic or neuropathic)
Step 3: Do NOT Use
- Standard PRP preparations (platelet gel, etc.)
- Blood bank-derived platelets
- Other autologous platelet therapies
Understanding the Contradiction with Recent Research
While recent meta-analyses 2, 3 and RCTs 4, 5, 6 from 2024-2026 show positive results for various PRP preparations, the IWGDF guideline takes precedence because:
Methodological rigor: The IWGDF performed a complete re-evaluation using updated GRADE methodology and newest benchmarking standards 1
Risk of bias assessment: The guideline identified that most positive PRP studies lack blinding and have high risk of bias 1
Standardization issues: The field suffers from poor standardization in PRP preparation methods, terminology, purity, and content 7
Product heterogeneity: "PRP" encompasses vastly different products—platelet gel, platelet concentrate, leukocyte-rich PRP, platelet-rich fibrin, etc.—with varying concentrations of platelets, leukocytes, and red blood cells 7
Real-world applicability: The guideline emphasizes resource requirements, cost-effectiveness, equity, and feasibility—not just efficacy in controlled trials 1
Critical Caveats and Pitfalls
Common Pitfall #1: Assuming All PRP is Equal
The leucocyte, platelet, and fibrin patch is fundamentally different from standard PRP preparations. It includes leucocytes and fibrin in a specific formulation with demonstrated efficacy in a high-quality trial 1. Do not extrapolate this recommendation to other PRP products.
Common Pitfall #2: Using PRP as First-Line Therapy
Never use any platelet therapy before optimizing standard care. The guideline consistently emphasizes these are adjunctive therapies only after standard care failure 1.
Common Pitfall #3: Ignoring Resource Requirements
The weekly venepuncture requirement for the leucocyte/platelet/fibrin patch is substantial. Ensure your facility has the expertise and resources before initiating therapy 1.
Common Pitfall #4: Relying on Low-Quality Evidence
Recent positive studies 4, 5, 6, 8 often lack the methodological rigor required by current standards. The IWGDF guideline's systematic approach reveals that when properly evaluated, most PRP preparations lack convincing evidence 1.
The Bottom Line for Clinical Practice
In real-world practice, do not routinely use PRP for diabetic foot ulcers. Focus on optimizing standard care: debridement, off-loading, infection control, and vascular optimization. If these fail and you have access to the specific autologous leucocyte, platelet, and fibrin patch product with appropriate resources, then consider it as an adjunctive therapy. All other forms of PRP lack sufficient evidence to justify their use, cost, and resource requirements in routine clinical practice.